Today, Victoza only has 4.6% of the GLP-1 market share for diabetes treatment. However, it can still make an impact on the management of
Other popular GLP-1 drugs, such as semaglutide (marketed as Ozempic and Wegovy), still maintain patent protection until 2024. Victoza had annual
Trulicityshave away at Victoza's market share. If Victoza's patent portfolio falls to another generic challenger or if another generic
Victoza remains Novo Nordisk's biggest seller, at DKK11. Victoza's U.S. GLP-1 volume market share has still valid, said Jørgensen.
Explore the explosive growth of the GLP-1 market Note: GLP-1 brands include Victoza Yet, there are still many unanswered questions
The next Victoza generics could launch as soon as December 2024. Once multiple Victoza generics are on the market, competition will further
Still, they're indicated for different treatments: Victoza for the We know there's other GLP-1 meds on the market that have similar
Annual Drug Patent Expirations for VICTOZA Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA.
Other information about Victoza The European Commission granted a marketing authorisation valid throughout the European Union for Victoza on . The
but he corners the market,,still.